8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Jan 6, 2026·SEC
Material company update
Nov 5, 2025·SEC
Compass Therapeutics, Inc.(CMPX)Earnings, Financials & Key Ratios
CMPX•NASDAQ
$1.85
$330M mkt cap·Price updated May 6, 2026
AboutCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$73M-32.7%
- Net Income-$66M-34.7%
- EPS (Diluted)-0.42-16.7%
- ROE-41.29%-14.5%
- ROIC-41.33%-4.3%
- Debt/Equity0.05-5.7%
CMPX Key Insights
Compass Therapeutics, Inc. (CMPX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 15.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CMPX Price & Volume
Compass Therapeutics, Inc. (CMPX) stock price & volume — 10-year historical chart
Loading chart...
CMPX Growth Metrics
Compass Therapeutics, Inc. (CMPX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.58%
Return on Capital
10 Years-59.26%
5 Years-45.58%
3 Years-37.95%
Last Year-43.21%
CMPX Recent Earnings
Compass Therapeutics, Inc. (CMPX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
Mar 5, 2026EPS
$0.09
Est $0.10
+10.0%
Revenue
—
Est $900,000
Q4 2025
Nov 5, 2025EPS
$0.08
Est $0.14
+42.9%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$0.14
Est $0.13
-7.7%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.12
Est $0.12
+0.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.09vs $0.10+10.0% | —vs $900,000 |
| Q4 2025 | Nov 5, 2025 | $0.08vs $0.14+42.9% | — |
| Q3 2025 | Aug 11, 2025 | $0.14vs $0.13-7.7% | — |
| Q2 2025 | May 8, 2025 | $0.12vs $0.12+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
CMPX Peer Comparison
Compass Therapeutics, Inc. (CMPX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 NKTX | 234.54M | 3.32 | -2.08 | -30.37% | 0.20 | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 EXEL | 12.37B | 48.70 | 17.52 | 6.98% | 35.08% | 40.21% | 0.08 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare CMPX vs Peers
Compass Therapeutics, Inc. (CMPX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CMPX Income Statement
Compass Therapeutics, Inc. (CMPX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'19 | Mar'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 850K | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | -100% |
| Cost of Goods Sold | 1.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -1.92M▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 850K▲ 0% | 0▼ 100.0% |
| Gross Margin % | - | - | - | - | - | - | 100% | - |
| Gross Profit Growth % | - | 100% | - | - | - | - | - | -100% |
| Operating Expenses | 38.31M | 34.05M | 27.81M | 81.88M | 41.66M | 50.36M | 57.48M | 72.84M |
| OpEx % of Revenue | - | - | - | - | - | - | 6761.76% | - |
| Selling, General & Admin | 11.22M | 11.6M | 12.91M | 10.93M | 11.66M | 12.24M | 15.13M | 16.87M |
| SG&A % of Revenue | - | - | - | - | - | - | 1780.35% | - |
| Research & Development | 27.09M | 22.45M | 14.9M | 20.34M | 30M | 38.12M | 42.34M | 55.97M |
| R&D % of Revenue | - | - | - | - | - | - | 4981.41% | - |
| Other Operating Expenses | 0 | 0 | 0 | 50.62M | 0 | 0 | 0 | 0 |
| Operating Income | -38.31M▲ 0% | -34.05M▲ 11.1% | -27.81M▲ 18.3% | -81.88M▼ 194.4% | -41.66M▲ 49.1% | -50.36M▼ 20.9% | -56.63M▼ 12.4% | -72.84M▼ 28.6% |
| Operating Margin % | - | - | - | - | - | - | -6661.76% | - |
| Operating Income Growth % | - | 11.12% | 18.32% | -194.41% | 49.13% | -20.91% | -12.43% | -28.63% |
| EBITDA | -36.39M | -31.93M | -25.41M | -80.26M | -39.75M | -48.47M | -54.87M | -72.84M |
| EBITDA Margin % | - | - | - | - | - | - | -6455.53% | - |
| EBITDA Growth % | - | 12.25% | 20.43% | -215.88% | 50.47% | -21.94% | -13.2% | -32.74% |
| D&A (Non-Cash Add-back) | 1.92M | 2.12M | 2.4M | 1.62M | 1.9M | 1.89M | 1.75M | 0 |
| EBIT | 0 | -34.05M | -27.81M | -81.81M | -41.66M | -50.36M | -56.63M | 0 |
| Net Interest Income | -104K | -485K | -820K | -341K | 0 | 0 | 7.3M | 0 |
| Interest Income | 663K | 743K | 88K | 29K | 2.36M | 0 | 7.3M | 6.35M |
| Interest Expense | 767K | 1.23M | 908K | 370K | 2.36M | 0 | 0 | 0 |
| Other Income/Expense | 233K | -601K | -1.66M | -299K | 2.43M | 7.87M | 7.25M | 6.35M |
| Pretax Income | -38.18M▲ 0% | -34.65M▲ 9.2% | -29.47M▲ 15.0% | -82.18M▼ 178.9% | -39.23M▲ 52.3% | -42.49M▼ 8.3% | -49.38M▼ 16.2% | -66.49M▼ 34.7% |
| Pretax Margin % | - | - | - | - | - | - | -5808.82% | - |
| Income Tax | 103K | 91K | 32K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.27% | -0.26% | -0.11% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -38.29M▲ 0% | -34.74M▲ 9.3% | -29.5M▲ 15.1% | -82.18M▼ 178.6% | -39.23M▲ 52.3% | -42.49M▼ 8.3% | -49.38M▼ 16.2% | -66.49M▼ 34.7% |
| Net Margin % | - | - | - | - | - | - | -5808.82% | - |
| Net Income Growth % | - | 9.25% | 15.09% | -178.58% | 52.27% | -8.33% | -16.19% | -34.66% |
| Net Income (Continuing) | -38.29M | -34.74M | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M | -66.49M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.66▲ 0% | -0.67▲ 91.3% | -0.52▲ 22.4% | -1.31▼ 151.9% | -0.35▲ 73.3% | -0.33▲ 5.7% | -0.36▼ 9.1% | -0.42▼ 16.7% |
| EPS Growth % | - | 91.25% | 22.39% | -151.92% | 73.28% | 5.71% | -9.09% | -16.67% |
| EPS (Basic) | -7.66 | -0.67 | -0.52 | -1.31 | -0.35 | -0.33 | -0.36 | -0.42 |
| Diluted Shares Outstanding | 5M | 52.11M | 56.22M | 62.87M | 105.19M | 127.03M | 137.11M | 157.69M |
| Basic Shares Outstanding | 5M | 52.11M | 56.22M | 62.87M | 105.19M | 127.03M | 137.11M | 157.69M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CMPX Balance Sheet
Compass Therapeutics, Inc. (CMPX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'19 | Mar'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 58.88M | 26.24M | 50.2M | 147.1M | 194.79M | 153.88M | 132.75M | 209.82M |
| Cash & Short-Term Investments | 57.51M | 25.3M | 47.08M | 144.51M | 186.61M | 152.46M | 126.72M | 208.91M |
| Cash Only | 57.51M | 25.3M | 47.08M | 144.51M | 34.95M | 24.23M | 43.48M | 30.64M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 151.66M | 128.23M | 83.24M | 178.26M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.37M | 0 | 0 | 0 | 8.18M | 1.42M | 6.03M | 913K |
| Total Non-Current Assets | 5.74M | 4.14M | 1.71M | 6.65M | 4.85M | 2.99M | 7.65M | 9.77M |
| Property, Plant & Equipment | 5.37M | 3.75M | 1.13M | 6.33M | 4.53M | 2.67M | 7.08M | 9.2M |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.12x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 262K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 115K | 392K | 583K | 320K | 320K | 320K | 568K | 568K |
| Total Assets | 64.63M▲ 0% | 30.38M▼ 53.0% | 51.91M▲ 70.9% | 153.76M▲ 196.2% | 199.65M▲ 29.8% | 156.88M▼ 21.4% | 140.4M▼ 10.5% | 219.59M▲ 56.4% |
| Asset Turnover | - | - | - | - | - | - | 0.01x | - |
| Asset Growth % | - | -52.99% | 70.87% | 196.19% | 29.84% | -21.42% | -10.5% | 56.4% |
| Total Current Liabilities | 8.46M | 9.82M | 10.1M | 10.63M | 16.17M | 7.8M | 8.87M | 13.97M |
| Accounts Payable | 1.73M | 629K | 1.06M | 867K | 3.38M | 4.09M | 2.25M | 1.58M |
| Days Payables Outstanding | 328.71 | - | - | - | - | - | - | - |
| Short-Term Debt | 3.69M | 5.58M | 7.47M | 0 | 0 | 0 | 0 | 1M |
| Deferred Revenue (Current) | 519K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.53M | 2.25M | 976K | 1.6M | 1.56M | 1.94M | 2.79M | 12.97M |
| Current Ratio | 6.96x | 2.67x | 4.97x | 13.84x | 12.05x | 19.73x | 14.96x | 15.02x |
| Quick Ratio | 6.96x | 2.67x | 4.97x | 13.84x | 12.05x | 19.73x | 14.96x | 15.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 140.93M | 139.16M | 1.87M | 3.05M | 1.84M | 536K | 6.3M | 8.83M |
| Long-Term Debt | 11.06M | 9.29M | 1.87M | 0 | 0 | 0 | 0 | 8.83M |
| Capital Lease Obligations | 0 | 0 | 0 | 3.05M | 1.84M | 536K | 6.3M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 129.87M | 129.87M | 0 | 0 | 0 | 0 | 1K | 0 |
| Total Liabilities | 149.4M | 148.98M | 11.97M | 13.68M | 18.01M | 8.34M | 15.17M | 22.8M |
| Total Debt | 14.75M | 14.87M | 9.33M | 4.04M | 2.94M | 1.73M | 6.63M | 9.83M |
| Net Debt | -42.76M | -10.43M | -37.74M | -140.48M | -32.01M | -22.5M | -36.85M | -20.81M |
| Debt / Equity | - | - | 0.23x | 0.03x | 0.02x | 0.01x | 0.05x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -49.95x | -27.73x | -30.63x | -221.30x | -17.65x | - | - | - |
| Total Equity | -84.77M▲ 0% | -118.6M▼ 39.9% | 39.95M▲ 133.7% | 140.08M▲ 250.7% | 181.64M▲ 29.7% | 148.54M▼ 18.2% | 125.23M▼ 15.7% | 196.79M▲ 57.1% |
| Equity Growth % | - | -39.9% | 133.68% | 250.68% | 29.67% | -18.22% | -15.69% | 57.14% |
| Book Value per Share | -16.95 | -2.28 | 0.71 | 2.23 | 1.73 | 1.17 | 0.91 | 1.25 |
| Total Shareholders' Equity | -84.77M | -118.6M | 39.95M | 140.08M | 181.64M | 148.54M | 125.23M | 196.79M |
| Common Stock | 2.39M | 1K | 5K | 10K | 13K | 13K | 13K | 18K |
| Retained Earnings | -87.16M | -121.91M | -151.41M | -233.59M | -272.81M | -315.31M | -364.68M | -431.17M |
| Treasury Stock | - | - | - | - | - | - | 0 | 0 |
| Accumulated OCI | -4.1M | 0 | 0 | 0 | -302K | 37K | 210K | 280K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CMPX Cash Flow Statement
Compass Therapeutics, Inc. (CMPX) cash flow — operating, investing & free cash flow history
| Line item | Mar'19 | Mar'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -33.68M | -31.74M | -26.8M | -19.67M | -34.13M | -40.62M | -44.85M | -49.14M |
| Operating CF Margin % | - | - | - | - | - | - | -5277.06% | - |
| Operating CF Growth % | - | 5.75% | 15.56% | 26.63% | -73.52% | -19.03% | -10.43% | -9.56% |
| Net Income | -38.29M | -34.74M | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M | -66.49M |
| Depreciation & Amortization | 1.92M | 2.12M | 2.4M | 1.62M | 1.9M | 1.89M | 1.75M | -1.4M |
| Stock-Based Compensation | 656K | 915K | 4.02M | 4.03M | 5.33M | 6.12M | 8.56M | 8.37M |
| Deferred Taxes | -261K | 109K | 837K | 50.58M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 121K | 116K | -960K | 41K | -871K | 5.97M | -1.65M | 10.38M |
| Working Capital Changes | 2.17M | -257K | -3.6M | 6.25M | -1.26M | -2.91M | -4.14M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 992K | -1.1M | 432K | -194K | 2.52M | 708K | -1.84M | -664K |
| Cash from Investing | -2.02M | -466K | 38K | -1.77M | -151.2M | 26.96M | 46.77M | -93.31M |
| Capital Expenditures | -2.02M | -466K | -106K | -1.57M | -212K | -30K | -44K | -25K |
| CapEx % of Revenue | - | - | - | - | - | - | 5.18% | - |
| Acquisitions | 0 | 0 | 144K | 116K | 176K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 144 | -318K | -150.99K | 27K | 0 | 0 |
| Cash from Financing | 64.03M | 37.63K | 48.54M | 118.61M | 75.76M | 2.94M | 17.34M | 129.61M |
| Debt Issued (Net) | - | - | - | - | - | - | 0 | 0 |
| Equity Issued (Net) | - | - | - | - | - | - | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -159 | 0 | 0 |
| Other Financing | 64.03M | 37.63K | -6.32M | -281K | -480K | -159K | -775K | 129.61M |
| Net Change in Cash | 28.33M▲ 0% | -32.21M▼ 213.7% | 21.77M▲ 167.6% | 97.17M▲ 346.3% | -109.57M▼ 212.8% | -10.72M▲ 90.2% | 19.25M▲ 279.7% | -12.84M▼ 166.7% |
| Free Cash Flow | -35.7M▲ 0% | -32.21M▲ 9.8% | -26.91M▲ 16.4% | -21.23M▲ 21.1% | -34.34M▼ 61.7% | -40.65M▼ 18.4% | -44.9M▼ 10.5% | -49.17M▼ 9.5% |
| FCF Margin % | - | - | - | - | - | - | -5282.24% | - |
| FCF Growth % | - | 9.78% | 16.45% | 21.09% | -61.71% | -18.38% | -10.46% | -9.51% |
| FCF per Share | -7.14 | -0.62 | -0.48 | -0.34 | -0.33 | -0.32 | -0.33 | -0.31 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.91x | 0.91x | 0.24x | 0.87x | 0.96x | 0.91x | 0.74x |
| Interest Paid | - | - | - | - | - | - | 0 | 0 |
| Taxes Paid | - | - | - | - | - | - | 0 | 0 |
CMPX Key Ratios
Compass Therapeutics, Inc. (CMPX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -73.85% | -91.3% | -24.38% | -25.74% | -36.07% | -41.29% |
| Return on Invested Capital (ROIC) | - | - | -946.85% | -6808.37% | -41.87% | -27.4% | -39.61% | -41.33% |
| Gross Margin | - | - | - | - | - | - | 100% | - |
| Net Margin | - | - | - | - | - | - | -5808.82% | - |
| Debt / Equity | - | - | 0.23x | 0.03x | 0.02x | 0.01x | 0.05x | 0.05x |
| Interest Coverage | -49.95x | -27.73x | -30.63x | -221.30x | -17.65x | - | - | - |
| FCF Conversion | 0.88x | 0.91x | 0.91x | 0.24x | 0.87x | 0.96x | 0.91x | 0.74x |
| Revenue Growth | - | - | - | - | - | - | - | -100% |
CMPX SEC Filings & Documents
Compass Therapeutics, Inc. (CMPX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CMPX Frequently Asked Questions
Compass Therapeutics, Inc. (CMPX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Compass Therapeutics, Inc. (CMPX) saw revenue decline by 100.0% over the past year.
Compass Therapeutics, Inc. (CMPX) reported a net loss of $66.5M for fiscal year 2025.
Dividend & Returns
Compass Therapeutics, Inc. (CMPX) has a return on equity (ROE) of -41.3%. Negative ROE indicates the company is unprofitable.
Compass Therapeutics, Inc. (CMPX) had negative free cash flow of $49.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More CMPX
Compass Therapeutics, Inc. (CMPX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates